Natco Pharma Limited — Board Meeting, 12-08-2025: Outcome of Board Meeting

NATCO Pharma's board has approved the financial results for the quarter ending June 30, 2025. Consolidated revenue stood at ₹1,390.6 Cr, with a net profit of ₹480.3 Cr. The company noted pricing pressure in the US market and higher R&D costs impacting this quarter.

The board declared an interim dividend of ₹2 per equity share. Additionally, shareholders' approval will be sought to increase the authorized share capital to ₹45 Cr, a key move for future flexibility. The notice for the 42nd Annual General Meeting was also approved.